menu
    • menu
    [{"orgOrder":0,"company":"Oqory","sponsor":"Vincerx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Termination","leadProduct":"ESG401","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Oqory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oqory \/ Vincerx Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Oqory \/ Vincerx Pharma"},{"orgOrder":0,"company":"Oqory","sponsor":"Vincerx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Merger","leadProduct":"ESG401","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Oqory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oqory \/ Vincerx Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Oqory \/ Vincerx Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Oqory

    Menu

    Oqory

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oqory

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oqory

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESG401

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Vincerx Pharma

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Vincerx Pharma Ends Reverse Merger Term Sheet, Explores Strategic Options

                            Details : Through the termination, Oqary will focus on advancing its own pipeline, including OQY-3258, an anti-TROP2 ADC currently being evaluated for TNBC.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            February 28, 2025

                            Lead Product(s) : ESG401

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Vincerx Pharma

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oqory

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Oqory

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESG401

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Vincerx Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.

                            Details : Under the merger agreement, Oqory will merge with Vincerx Pharma, enhancing the combined company's pipeline. This includes OQY-3258, an anti-TROP2 ADC currently being evaluated for TNBC.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            December 27, 2024

                            Lead Product(s) : ESG401

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Vincerx Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth